{
  "source": "PA-Notification-Ebglyss.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2025 P 1472-1\nProgram Prior Authorization/Notification\nMedication Ebglyss™ (lebrikizumab-lbkz)\nP&T Approval Date 3/2025\nEffective Date 5/1/2025\n1. Background:\nEbglyss (lebrikizumab-lbkz) is an interleukin-13 antagonist indicated for the treatment of adults\nand pediatric patients 12 years of age and older who weigh at least 40 kg with moderate to\nsevere atopic dermatitis whose disease is not adequately controlled with topical prescription\ntherapies or when those therapies are not advisable. Ebglyss can be used with or without topical\ncorticosteroids.\n2. Coverage Criteriaa:\nA. Atopic Dermatitis\n1. Initial Authorization\na. Ebglyss will be approved based on all of the following criteria:\n(1) Diagnosis of moderate to severe atopic dermatitis\n-AND-\n(2) History of failure, contraindication, or intolerance to topical therapies\n-AND-\n(3) Patient is not receiving Ebglyss in combination with either of the following:\n(a) Biologic immunomodulator [e.g., Adbry (tralokinumab-ldrm), Dupixent\n(dupilumab)]\n(b) Janus kinase inhibitor [e.g., Cibinqo (abrocitinib), Opzelura (topical\nruxolitinib), Rinvoq (upadacitinib), Xeljanz/XR (tofacitinib)]\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Ebglyss will be approved based on both of the following criteria:\n(1) Documentation of positive clinical response to Ebglyss therapy\n-AND-\n© 2025 UnitedHealthcare Services, Inc.\n1\n(2) Patient is not receiving Ebglyss in combination with either of the following:\n(a) Biologic immunomodulator [e.g., Adbry (tralokinumab-ldrm), Dupixent\n(dupilumab)]\n(b) Janus kinase inhibitor [e.g., Cibinqo (abrocitinib), Opzelura (topical\nruxolitinib), Rinvoq (upadacitinib), Xeljanz/XR (tofacitinib)]\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs",
    "ths.\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply.\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-\nauthorization based solely on previous claim/medication history, diagnosis codes (ICD-10)\nand/or claim logic. Use of automated approval and re-approval processes varies by program\nand/or therapeutic class.\n• Supply limits may be in place.\n4. References:\n1. Ebglyss [package insert]. Indianapolis, IN: Eli Lilly and Company; September 2024.\nProgram Prior Authorization/Notification - Ebglyss (lebrikizumab-lbkz)\nChange Control\n3/2025 New program.\n© 2025 UnitedHealthcare Services, Inc.\n2"
  ]
}